Incannex Healthcare Limited

$3.71+0.27%(+$0.01)
TickerSpark Score
60/100
Mixed
80
Valuation
40
Profitability
55
Growth
76
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IXHL research report →

52-Week Range3% of range
Low $2.49
Current $3.71
High $49.80

Companywww.incannex.com.au

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases.

CEO
Joel Bradley Latham
IPO
2022
Employees
9
HQ
Sydney, NSW, AU

Price Chart

-48.47% · this period
$48.90$25.73$2.56May 20Nov 18May 20

Valuation

Market Cap
$42.61M
P/E
-0.78
P/S
495.45
P/B
0.59
EV/EBITDA
0.45
Div Yield
0.00%

Profitability

Gross Margin
100.00%
Op Margin
-37921.41%
Net Margin
-64630.36%
ROE
-190.00%
ROIC
-44.33%

Growth & Income

Revenue
$86.00K · 378.70%
Net Income
$-46,885,000 · -69.66%
EPS
$-40.80 · -1092.98%
Op Income
$-23,789,000
FCF YoY
22.34%

Performance & Tape

52W High
$49.80
52W Low
$2.49
50D MA
$3.66
200D MA
$9.74
Beta
2.87
Avg Volume
561.02K

Get TickerSpark's AI analysis on IXHL

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Nov 14, 25Valentine Troyother11,302,608
Nov 14, 25Clark Robertother1,686,956
Nov 14, 25Widdows Peterother1,686,956
Nov 14, 25Swan Josephother869,565
Nov 14, 25Latham Joelother22,608,692
Nov 14, 25Anastassov Georgeother1,686,956
Oct 23, 24Barbato Luigi M.other100,476
Oct 21, 24Barbato Luigi M.other0
Jun 30, 24Swan Josephother0
Dec 21, 23Valentine Troyother670,000

Our IXHL Coverage

We haven't published any research on IXHL yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate IXHL Report →

Similar Companies